Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CStone Pharmaceuticals ( (HK:2616) ) just unveiled an update.
CStone Pharmaceuticals announced the inclusion of GAVRETO® (pralsetinib) in China’s National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion marks a significant milestone for CStone, enhancing its market presence in Greater China and potentially increasing accessibility for patients with RET fusion-positive cancers. The drug, developed in collaboration with Blueprint Medicines, is already approved in several regions, including the U.S., Hong Kong, and Taiwan, for treating specific types of cancer, and this development is expected to strengthen CStone’s position in the oncology sector.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015 and listed on the Hong Kong Stock Exchange, is an innovation-driven biopharmaceutical company focused on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications covering nine indications, with a pipeline featuring promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.
Average Trading Volume: 15,662,792
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.24B
See more insights into 2616 stock on TipRanks’ Stock Analysis page.